Ilyang Pharm advances to the global market with leukemia treatment, ‘Supect’
Ilyang Pharm(CEO Dong-yun Kim) attracted interest of the global market as announcing 3 results of the final clinical trial of the Asia’s first leukemia treatment, ‘Supect(generic name: radotinib).’
At the ‘57th American Society of Hematology(ASH) Meeting’ in Orlando on 7th of December, Professor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
